Supreme Court Mifepristone Decision Sets High Bar For FDA Suits, But Risks To Agency Authority Linger
The US Supreme Court abortion pill opinion sets a high bar for FDA lawsuits, but future tests of FDA's authority remain a risk. • Source: Shutterstock 
